CoChat

Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes

Gómez‐Perez, Francisco J., Fanghänel‐Salmón, Guillermo, Antonio Barbosa, Juan, Montes‐Villarreal, Juan, Berry, Rhona A., Warsi, Ghulam, Gould, Errol M. · 2002 · Diabetes/Metabolism Research and Reviews
Cited by 113

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background: Type 2 diabetes is a growing problem in Mexico. The present study was undertaken to evaluate the efficacy and safety of rosiglitazone 2 mg or 4 mg twice daily (bd) in combination with metformin 2.5 g/day in Mexican patients whose type 2 diabetes was inadequately controlled with metformin alone. Methods: This randomized, double‐blind, placebo‐controlled study was conducted at four centers in Mexico. A total of 116 patients were randomized to metformin 2.5 g/day plus placebo (n=39), metformin 2.5 g/day plus rosiglitazone 2 mg bd (n=37), or metformin 2.5 g/day plus rosiglitazone 4 mg bd (n=40) for 26 weeks. Results: Mean hemoglobin A 1c (HbA 1c) levels decreased significantly from baseline to Week 26 in the rosiglitazone 2 mg bd (−0.7%; p=0.0052) and 4 mg bd (−1.2%; p=0.0008) groups, but increased in the placebo group (+0.3%; p=0.2651). Mean fasting plasma glucose and fructosamine levels also improved significantly with metformin plus rosiglitazone therapy in a dose‐ordered manner compared with placebo (p≤0.0019 and p=0.0006, respectively). C‐peptide and immunoreactive insulin levels were decreased from baseline in both rosiglitazone groups. Although mean increases in total cholesterol, low‐density lipoprotein (LDL)‐cholesterol, and high‐density lipoprotein (HDL)‐cholesterol were observed in the rosiglitazone groups, the total cholesterol:HDL‐cholesterol ratio remained unchanged. The proportion of patients with one or more adverse events was similar across all three groups. There were no cases of hepatotoxicity. Conclusion: Addition of rosiglitazone 2 mg bd and 4 mg bd to metformin therapy improved glycemic control in Mexican patients whose type 2 diabetes was inadequately controlled by metformin alone. Furthermore, the combination of rosiglitazone plus metformin was well tolerated. Copyright © 2002 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.264

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

Metadata

Authors
Gómez‐Perez, F. J., Fanghänel‐Salmón, G., Antonio Barbosa, J., Montes‐Villarreal, J., Berry, R. A., Warsi, G., & Gould, E. M.
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2002-03
Volume
18
Issue
2
Pages
127-134
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W2169775081
Cited by
113
References
8
FWCI
8.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.